<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Measurement of ACTH, CRH, and other hypothalamic and pituitary peptides
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Measurement of ACTH, CRH, and other hypothalamic and pituitary peptides
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Measurement of ACTH, CRH, and other hypothalamic and pituitary peptides
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Lynnette K Nieman, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            André Lacroix, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Katya Rubinow, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Sep 29, 2019.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Measurements of plasma corticotropin (ACTH) are extremely useful in the diagnosis of both Cushing's syndrome and adrenal insufficiency. In contrast, corticotropin-releasing hormone (CRH) is rarely measured in peripheral plasma or serum because the concentrations are much lower than and do not correlate well with those in the hypothalamic-hypophysial portal plasma. This is because of contribution from nonhypothalamic sources (eg, the gastrointestinal tract). The measurement of ACTH, CRH, and other related hypothalamic and pituitary peptides will be reviewed here. The approaches to the diagnosis of Cushing's syndrome and adrenal insufficiency are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/151.html" rel="external">
          "Establishing the diagnosis of Cushing syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/154.html" rel="external">
          "Determining the etiology of adrenal insufficiency in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ACTH
         </span>
         <span class="headingEndMark">
          —
         </span>
         The current commercially available two-site immunometric assays have an analytical sensitivity between 0.6 and 9 pg/mL (0.12 to 19.8 pmol/L) [
         <a href="#rid1">
          1
         </a>
         ]. However, performance differs between assays and should be considered when interpreting patient results [
         <a href="#rid2">
          2-4
         </a>
         ]. Furthermore, the most common platform immunoassay in use in the United States gives significantly different results in the critical range of 9 to 118 pg/mL (2 to 26.2 pmol/L) compared with a gold standard immunometric assay [
         <a href="#rid5">
          5
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Normal values
         </span>
         <span class="headingEndMark">
          —
         </span>
         Plasma corticotropin (ACTH) concentrations are usually between 10 and 60 pg/mL (2.2 and 13.3 pmol/L) at 8 AM. The values decrease during the waking hours and are usually less than 20 pg/mL (4.5 pmol/L) at 4 PM and less than 10 pg/mL (2.2 pmol/L), usually less than 5 pg/mL (1.1 pmol/L), within one hour after the usual time of falling sleep. This circadian rhythm in plasma ACTH concentrations is the cause of the parallel changes in cortisol secretion by the adrenal glands and the resulting rhythm in serum cortisol concentrations.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Interpretation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The time of day at which the sample is taken is an important determinant of the utility of the measurement of plasma ACTH, which is often best interpreted with a simultaneous measurement of serum cortisol.
        </p>
        <p>
         In evaluating patients with
         <strong>
          adrenal insufficiency
         </strong>
         , measurements should be made in the morning, if possible, when plasma ACTH and serum cortisol concentrations are usually at their highest value [
         <a href="#rid6">
          6
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/154.html" rel="external">
          "Determining the etiology of adrenal insufficiency in adults"
         </a>
         ). However, in urgent or emergent evaluation of patients with potential adrenal insufficiency (eg, in the intensive care unit or emergency department), blood samples should be drawn at any time before administration of glucocorticoid therapy.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Morning (8 AM [range 6 to 10 AM]) plasma ACTH is high and serum cortisol is low in primary adrenal insufficiency. Elevated plasma ACTH with a concurrent low serum cortisol at any time can indicate primary adrenal insufficiency.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Both plasma ACTH and serum cortisol values are at the low end of the normal range or undetectable in secondary adrenal insufficiency (ie, hypopituitarism or isolated ACTH deficiency). This is also true in tertiary adrenal insufficiency (hypothalamic corticotropin-releasing hormone [CRH] deficiency), although this is rare and difficult to establish clinically. These values are inappropriately low for the degree of hypocortisolism.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In congenital adrenal hyperplasia, early morning plasma ACTH values tend to be high, whereas serum cortisol may be normal or low, depending upon the severity of the enzyme deficiency.
        </p>
        <p>
        </p>
        <p>
         Late evening plasma ACTH and serum cortisol values are of little value in diagnosing primary adrenal insufficiency or congenital adrenal hyperplasia, although evening plasma ACTH concentrations tend to be somewhat high in these disorders.
        </p>
        <p>
         In the different forms of
         <strong>
          Cushing's syndrome
         </strong>
         , plasma ACTH and serum cortisol concentrations are most helpful when measured in the late evening, the time at which the concentrations are usually near their nadir in normal persons. These samples must be taken without stress, and this is impractical in most clinical circumstances. Whereas morning values may be within the normal range, there is loss of the normal circadian rhythm in secretion in Cushing's syndrome and the evening values are usually higher than normal. However, for the diagnostic purpose of distinguishing between ACTH-dependent tumors and primary adrenal causes of Cushing's syndrome, ACTH can be measured at any time [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/151.html" rel="external">
          "Establishing the diagnosis of Cushing syndrome"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with Cushing's syndrome due to adrenocortical tumors, bilateral micronodular dysplasia, or other primary adrenocortical disorders (ie, ACTH-independent Cushing's syndrome), plasma ACTH concentrations are low, often undetectable, but serum cortisol concentrations are high. (See
         <a class="medical medical_review" href="/z/d/html/137.html" rel="external">
          "Clinical presentation and evaluation of adrenocortical tumors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/148.html" rel="external">
          "Cushing's syndrome due to primary bilateral macronodular adrenal hyperplasia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/152.html" rel="external">
          "Cushing syndrome due to primary pigmented nodular adrenocortical disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with Cushing's disease or ectopic ACTH syndrome (ie, ACTH-dependent Cushing's syndrome), the late evening plasma ACTH and serum cortisol concentrations are both high. The values for both tend to be higher in the ectopic ACTH syndrome than in Cushing's disease, but there is considerable overlap (see
         <a class="medical medical_review" href="/z/d/html/156.html" rel="external">
          "Establishing the cause of Cushing syndrome", section on 'ACTH-dependent CS (ACTH &gt;20 pg/mL)'
         </a>
         ). The morning plasma ACTH levels are often normal, but can be inappropriately elevated for the degree of hypercortisolism.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Pitfalls in measurement
         </span>
         <span class="headingEndMark">
          —
         </span>
         Several factors may influence plasma ACTH assay results:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         ACTH may be unstable in blood at room temperature, is cleaved by enzymes in blood cells and platelets, and adheres to glass and some plastic surfaces [
         <a href="#rid8">
          8
         </a>
         ]. Therefore, how blood is collected and plasma is prepared and stored may markedly affect the measured ACTH concentration; the severity of this problem varies with the antibodies used in the assays [
         <a href="#rid9">
          9
         </a>
         ]. In general, it is recommended that ACTH blood samples be drawn into plastic tubes with EDTA and kept on ice until centrifugation, separation, and freezing of the plasma sample.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         ACTH secretion in primary adrenal insufficiency, congenital adrenal hyperplasia, and ACTH-dependent Cushing's syndrome is episodic. Because the plasma disappearance half-time is measured in minutes, measurement of more than two samples may be useful, particularly if the initial result is equivocal. This can be done by obtaining samples at the same time on multiple days or by obtaining samples 30 to 60 minutes apart on the same day.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Normal subjects and patients with adrenal disorders may respond rapidly to stress with increased ACTH secretion. For this reason, blood samples should be obtained with indwelling needles or catheters. Measurements in samples that require more than two or three minutes to obtain by venipuncture must be interpreted with caution, if high. For the same reason, it is best not to obtain post-sleep values the first night in the hospital before the patient is acclimated to a new environment.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with major depressive disorder, particularly older patients with severe melancholic depression, may have increased plasma ACTH concentrations [
         <a href="#rid10">
          10
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/151.html" rel="external">
          "Establishing the diagnosis of Cushing syndrome", section on 'Exclude physiologic hypercortisolism'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One must be certain that the patient is not taking or has not recently taken glucocorticoids, which can acutely or chronically suppress hypothalamic-pituitary-adrenal function.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Two-site "sandwich" immunoassays for ACTH use two different monoclonal or affinity-purified polyclonal antibodies. They may not react with proopiomelanocortin (POMC) or forms intermediate between POMC and ACTH [
         <a href="#rid1">
          1,11,12
         </a>
         ]. This specificity may be a
         <strong>
          disadvantage
         </strong>
         in diagnosing the ectopic ACTH syndrome, in which a large percentage of circulating immunoreactive ACTH may represent incompletely processed or unprocessed POMC (see
         <a class="local">
          'Other POMC-derived peptides'
         </a>
         below). POMC concentrations can be reliably measured only with a two-site POMC immunoassay [
         <a href="#rid13">
          13
         </a>
         ], although this measurement is not widely commercially available.
        </p>
        <p>
        </p>
        <p>
         In addition, excessive concentrations of ACTH fragments, such as ACTH-(1-24), can compete for binding to one or the other of the two antibodies, preventing intact ACTH from coupling to both antibodies and causing factitiously low ACTH concentrations [
         <a href="#rid14">
          14
         </a>
         ]. This is unlikely to be a problem in measuring endogenous ACTH.
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h1">
          CRH
         </span>
         <span class="headingEndMark">
          —
         </span>
         Like many other peptide hormones, corticotropin-releasing hormone (CRH) is measured by radioimmunoassay or enzyme-linked immunoassay [
         <a href="#rid15">
          15
         </a>
         ]. In humans, CRH is largely bound to a plasma CRH-binding protein [
         <a href="#rid16">
          16,17
         </a>
         ] and must be extracted by immunoaffinity chromatography or methanol before assay [
         <a href="#rid18">
          18,19
         </a>
         ].
        </p>
        <p>
         Peripheral plasma CRH concentrations range from about 1 to 10 pg/mL (0.2 to 2.2 pmol/L), increasing progressively during pregnancy to as high as 2700 pg/mL (585 pmol/L) [
         <a href="#rid18">
          18,20
         </a>
         ]. The increased CRH in peripheral plasma in pregnant women is presumably produced by the placenta [
         <a href="#rid21">
          21
         </a>
         ]. Most of the CRH is bound to CRH-binding protein [
         <a href="#rid22">
          22
         </a>
         ]. The net effect of the increase in CRH is that maternal pituitary corticotropin (ACTH) secretion, plasma ACTH and serum cortisol concentrations, and urinary and salivary cortisol excretion increase during pregnancy [
         <a href="#rid23">
          23
         </a>
         ]. This effect is gradual, apparently because the concentration of the CRH-binding protein falls during late pregnancy, resulting in a greater concentration of free bioactive CRH [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p>
         Despite an early report to the contrary [
         <a href="#rid25">
          25
         </a>
         ], peripheral plasma CRH concentrations do not correlate with plasma ACTH or serum cortisol concentrations or with altered hypothalamic-pituitary-adrenal axis function (eg, in primary adrenal insufficiency or Cushing's syndrome, or during insulin-induced hypoglycemia or
         <a class="drug drug_general" data-topicid="10156" href="/z/d/drug information/10156.html" rel="external">
          metyrapone
         </a>
         administration). Some investigators reported a correlation between plasma CRH and plasma ACTH or serum cortisol in pregnancy [
         <a href="#rid26">
          26
         </a>
         ], but others have not [
         <a href="#rid27">
          27,28
         </a>
         ].
        </p>
        <p>
         Plasma CRH concentrations are also high in the ectopic CRH syndrome, which is the one clinical setting in which measuring peripheral plasma CRH is of value [
         <a href="#rid29">
          29-31
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h1">
          OTHER POMC-DERIVED PEPTIDES
         </span>
         <span class="headingEndMark">
          —
         </span>
         There is currently no clinical indication for measuring
         <strong>
          <em>
          </em>
         </strong>
         non-corticotropin (ACTH) proopiomelanocortin (POMC) hormones.
         <strong>
          <em>
          </em>
         </strong>
         POMC is the ACTH precursor peptide. It is also the source of beta-lipotropin (beta-LPH). In addition, ACTH and beta-LPH are cleaved further to yield alpha- and beta-melanocyte-stimulating hormone (alpha-MSH and beta-MSH), beta-endorphin, and met-enkephalin.
        </p>
        <p>
         There is disagreement about the degree to which POMC is normally processed in the anterior pituitary [
         <a href="#rid32">
          32,33
         </a>
         ], and differential processing may take place in different subpopulations of anterior pituitary corticotrophs. Therefore, POMC-derived peptides may not necessarily be released in equimolar concentrations. Furthermore, they appear to be metabolized at different rates, so that one may persist longer than others in the circulation. They are, however, released in concert so that their concentrations change in parallel [
         <a href="#rid34">
          34
         </a>
         ]. Thus, the peripheral plasma concentrations of these hormones provide a direct index of pituitary secretion.
        </p>
        <p>
         Radioimmunoassays and enzyme-linked immunoassays have been developed for POMC itself and other POMC-derived peptides, including alpha- and beta-MSH, beta-LPH, beta-endorphin, the N-terminal peptide of POMC, and the joining peptide between the N-terminal peptide and ACTH [
         <a href="#rid13">
          13,32,35-39
         </a>
         ]. These assays have not been validated for routine clinical use.
        </p>
        <p>
         Some early studies suggested that measurement of POMC or non-ACTH POMC fragments might have value in the diagnosis of ectopic ACTH secretion [
         <a href="#rid40">
          40
         </a>
         ], or as a marker of tumor aggressivity in pituitary and non-pituitary tumors [
         <a href="#rid41">
          41
         </a>
         ]. [
         <a href="#rid42">
          42
         </a>
         ]. However, measurement of non-ACTH POMC hormones is currently not clinically indicated.
        </p>
        <p class="headingAnchor" id="H987742721">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112709.html" rel="external">
          "Society guideline links: Diagnosis and treatment of Cushing syndrome"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/112295.html" rel="external">
          "Society guideline links: Adrenal insufficiency"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          SUMMARY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Measurements of plasma corticotropin (ACTH) are important for the diagnosis of both Cushing's syndrome and adrenal insufficiency. Corticotropin-releasing hormone (CRH) measurements are less useful clinically, but are sometimes used in the evaluation of ectopic CRH syndrome. (See
         <a class="local">
          'CRH'
         </a>
         above.)
        </p>
        <p>
         When evaluating patients with
         <strong>
          adrenal insufficiency
         </strong>
         , measurements should be made in the morning if possible, when plasma ACTH and serum cortisol concentrations are usually at their highest value. (See
         <a class="local">
          'ACTH'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/154.html" rel="external">
          "Determining the etiology of adrenal insufficiency in adults"
         </a>
         .)
        </p>
        <p>
         However, elevated plasma ACTH in the presence of low serum cortisol can be diagnostic for primary adrenal insufficiency at any time of day.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In primary adrenal insufficiency, early morning (6 to 10 AM) plasma ACTH is high and serum cortisol is low in primary adrenal insufficiency.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In secondary and tertiary adrenal insufficiency, plasma ACTH values are low or within the reference range (but inappropriately low for the degree of hypocortisolism). Serum cortisol is usually low or at the low end of the reference range.
        </p>
        <p>
        </p>
        <p>
         In the different forms of
         <strong>
          Cushing's syndrome
         </strong>
         , plasma ACTH and serum cortisol concentrations can be measured at any time.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with Cushing's syndrome due to adrenocortical tumors, bilateral micronodular dysplasia, or other primary adrenocortical disorders (ie, ACTH-independent Cushing's syndrome), plasma ACTH concentrations are low, often undetectable, but serum cortisol concentrations are high. (See
         <a class="local">
          'ACTH'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/137.html" rel="external">
          "Clinical presentation and evaluation of adrenocortical tumors"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/148.html" rel="external">
          "Cushing's syndrome due to primary bilateral macronodular adrenal hyperplasia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/152.html" rel="external">
          "Cushing syndrome due to primary pigmented nodular adrenocortical disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In patients with Cushing's disease or ectopic ACTH syndrome (ie, ACTH-dependent Cushing's syndrome), the plasma ACTH and late evening serum cortisol concentrations are both high. Plasma ACTH can be within the reference range in the morning, but is usually inappropriately elevated for the degree of hypercortisolism. The values for both tend to be higher in the ectopic ACTH syndrome than in Cushing's disease, but there is considerable overlap. (See
         <a class="medical medical_review" href="/z/d/html/156.html" rel="external">
          "Establishing the cause of Cushing syndrome", section on 'ACTH-dependent CS (ACTH &gt;20 pg/mL)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Measurement of CRH is not indicated for clinical purposes except in the setting of suspected ectopic CRH secretion in Cushing’s syndrome. (See
         <a class="local">
          'CRH'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Measurement of non-ACTH proopiomelanocortin (POMC) hormones is not clinically indicated. (See
         <a class="local">
          'Other POMC-derived peptides'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3323838529">
         <span class="h1">
          ACKNOWLEDGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The views expressed in this topic are those of the author(s) and do not reflect the official views or policy of the United States Government or its components.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Talbot JA, Kane JW, White A. Analytical and clinical aspects of adrenocorticotrophin determination. Ann Clin Biochem 2003; 40:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lindsay JR, Shanmugam VK, Oldfield EH, et al. A comparison of immunometric and radioimmunoassay measurement of ACTH for the differential diagnosis of Cushing's syndrome. J Endocrinol Invest 2006; 29:983.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilkinson CW, Raff H. Comparative evaluation of a new immunoradiometric assay for corticotropin. Clin Chem Lab Med 2006; 44:669.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abellán-Galiana P, Fajardo-Montañana C, Riesgo-Suárez P, et al. Prognostic usefulness of ACTH in the postoperative period of Cushing's disease. Endocr Connect 2019; 8:1262.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raff H. Immulite vs Scantibodies IRMA plasma ACTH assay. Clin Chem 2008; 54:1409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bornstein SR, Allolio B, Arlt W, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101:364.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klose M, Kofoed-Enevoldsen A, Ostergaard Kristensen L. Single determination of plasma ACTH using an immunoradiometric assay with high detectability differentiates between ACTH-dependent and -independent Cushing's syndrome. Scand J Clin Lab Invest 2002; 62:33.
          </a>
         </li>
         <li class="breakAll">
          Orth DN. Adrenocorticotropic hormone (ACTH). In: Methods of Hormone Radioimmunoassay, Jaffe BM, Behrman HR (Eds), Academic Press, Inc., New York 1979. p.245.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Besser GM, Orth DN, Nicholson WE, et al. Dissociation of the disappearance of bioactive and radioimmunoreactive ACTH from plasma in man. J Clin Endocrinol Metab 1971; 32:595.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pfohl B, Sherman B, Schlechte J, Stone R. Pituitary-adrenal axis rhythm disturbances in psychiatric depression. Arch Gen Psychiatry 1985; 42:897.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fukata J, Naitoh Y, Usui T, et al. Two-site immunoradiometric assay for adrenocorticotrophin: a cautionary study about the reactivity to its precursor molecules. Endocrinol Jpn 1989; 36:155.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsuchiya K, Minami I, Tateno T, et al. Malignant gastric carcinoid causing ectopic ACTH syndrome: discrepancy of plasma ACTH levels measured by different immunoradiometric assays. Endocr J 2005; 52:743.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tsigos C, Crosby SR, Gibson S, et al. Proopiomelanocortin is the predominant adrenocorticotropin-related peptide in human cerebrospinal fluid. J Clin Endocrinol Metab 1993; 76:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raff H, Findling JW, Wong J. Short loop adrenocorticotropin (ACTH) feedback after ACTH-(1-24) injection in man is an artifact of the immunoradiometric assay. J Clin Endocrinol Metab 1989; 69:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicholson WE, DeCherney GS, Jackson RV, et al. Plasma distribution, disappearance half-time, metabolic clearance rate, and degradation of synthetic ovine corticotropin-releasing factor in man. J Clin Endocrinol Metab 1983; 57:1263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Orth DN, Mount CD. Specific high-affinity binding protein for human corticotropin-releasing hormone in normal human plasma. Biochem Biophys Res Commun 1987; 143:411.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Behan DP, Linton EA, Lowry PJ. Isolation of the human plasma corticotrophin-releasing factor-binding protein. J Endocrinol 1989; 122:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sasaki A, Shinkawa O, Margioris AN, et al. Immunoreactive corticotropin-releasing hormone in human plasma during pregnancy, labor, and delivery. J Clin Endocrinol Metab 1987; 64:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ellis MJ, Livesey JH, Donald RA. Circulating plasma corticotrophin-releasing factor-like immunoreactivity. J Endocrinol 1988; 117:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Campbell EA, Linton EA, Wolfe CD, et al. Plasma corticotropin-releasing hormone concentrations during pregnancy and parturition. J Clin Endocrinol Metab 1987; 64:1054.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Makrigiannakis A, Zoumakis E, Margioris AN, et al. The corticotropin-releasing hormone (CRH) in normal and tumoral epithelial cells of human endometrium. J Clin Endocrinol Metab 1995; 80:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salminen-Lappalainen K, Laatikainen T. Binding of corticotropin-releasing hormone (CRH) in maternal and fetal plasma and in amniotic fluid. Clin Chim Acta 1990; 195:57.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goland RS, Conwell IM, Warren WB, Wardlaw SL. Placental corticotropin-releasing hormone and pituitary-adrenal function during pregnancy. Neuroendocrinology 1992; 56:742.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Linton EA, Perkins AV, Woods RJ, et al. Corticotropin releasing hormone-binding protein (CRH-BP): plasma levels decrease during the third trimester of normal human pregnancy. J Clin Endocrinol Metab 1993; 76:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suda T, Tomori N, Yajima F, et al. Immunoreactive corticotropin-releasing factor in human plasma. J Clin Invest 1985; 76:2026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sasaki A, Shinkawa O, Yoshinaga K. Placental corticotropin-releasing hormone may be a stimulator of maternal pituitary adrenocorticotropic hormone secretion in humans. J Clin Invest 1989; 84:1997.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeske W, Soszyński P, Rogoziński W, et al. Plasma GHRH, CRH, ACTH, beta-endorphin, human placental lactogen, GH and cortisol concentrations at the third trimester of pregnancy. Acta Endocrinol (Copenh) 1989; 120:785.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allolio B, Hoffmann J, Linton EA, et al. Diurnal salivary cortisol patterns during pregnancy and after delivery: relationship to plasma corticotrophin-releasing-hormone. Clin Endocrinol (Oxf) 1990; 33:279.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fjellestad-Paulsen A, Abrahamsson PA, Bjartell A, et al. Carcinoma of the prostate with Cushing's syndrome. A case report with histochemical and chemical demonstration of immunoreactive corticotropin-releasing hormone in plasma and tumoral tissue. Acta Endocrinol (Copenh) 1988; 119:506.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jessop DS, Cunnah D, Millar JG, et al. A phaeochromocytoma presenting with Cushing's syndrome associated with increased concentrations of circulating corticotrophin-releasing factor. J Endocrinol 1987; 113:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schteingart DE, Lloyd RV, Akil H, et al. Cushing's syndrome secondary to ectopic corticotropin-releasing hormone-adrenocorticotropin secretion. J Clin Endocrinol Metab 1986; 63:770.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilson RE, Orth DN, Nicholson WE, et al. Human gamma-lipotropin radioimmunoassay: identification of immunoreactive gamma-lipotropin in human plasma and tissue. J Clin Endocrinol Metab 1981; 53:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liotta AS, Suda T, Krieger DT. beta-Lipotropin is the major opioid-like peptide of human pituitary and rat pars distalis: lack of significant beta-endorphin. Proc Natl Acad Sci U S A 1978; 75:2950.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jackson RV, DeCherney GS, DeBold CR, et al. Synthetic ovine corticotropin-releasing hormone: simultaneous release of proopiolipomelanocortin peptides in man. J Clin Endocrinol Metab 1984; 58:740.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Usategui R, Oliver C, Vaudry H, et al. Immunoreactive alpha-MSH and ACTH levels in rat plasma and pituitary. Endocrinology 1976; 98:189.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bertagna XY, Stone WJ, Nicholson WE, et al. Simultaneous assay of immunoreactive beta-lipotropin, gamma-lipotropin, and beta-endorphin in plasma of normal human subjects, patients with ACTH/lipotropin hypersecretory syndromes, and patients undergoing chronic hemodialysis. J Clin Invest 1981; 67:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hale AC, Ratter SJ, Tomlin SJ, et al. Measurement of immunoreactive gamma-MSH in human plasma. Clin Endocrinol (Oxf) 1984; 21:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pettibone DJ, Mueller GP. Clonidine releases immunoreactive beta-endorphin from rat para distalis. Brain Res 1981; 221:409.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chan JS, Seidah NG, Chrétien M. Measurement of N-terminal (1-76) of human proopiomelanocortin in human plasma: correlation with adrenocorticotropin. J Clin Endocrinol Metab 1983; 56:791.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuhn JM, Proeschel MF, Seurin DJ, et al. Comparative assessment of ACTH and lipotropin plasma levels in the diagnosis and follow-up of patients with Cushing's syndrome: a study of 210 cases. Am J Med 1989; 86:678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Raffin-Sanson ML, Massias JF, Dumont C, et al. High plasma proopiomelanocortin in aggressive adrenocorticotropin-secreting tumors. J Clin Endocrinol Metab 1996; 81:4272.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibson S, Ray DW, Crosby SR, et al. Impaired processing of proopiomelanocortin in corticotroph macroadenomas. J Clin Endocrinol Metab 1996; 81:497.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 171 Version 16.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14503983" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Analytical and clinical aspects of adrenocorticotrophin determination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17259795" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : A comparison of immunometric and radioimmunoassay measurement of ACTH for the differential diagnosis of Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16681443" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Comparative evaluation of a new immunoradiometric assay for corticotropin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31394502" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Prognostic usefulness of ACTH in the postoperative period of Cushing's disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18664454" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Immulite vs Scantibodies IRMA plasma ACTH assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26760044" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12002411" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Single determination of plasma ACTH using an immunoradiometric assay with high detectability differentiates between ACTH-dependent and -independent Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12002411" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Single determination of plasma ACTH using an immunoradiometric assay with high detectability differentiates between ACTH-dependent and -independent Cushing's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4325282" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Dissociation of the disappearance of bioactive and radioimmunoreactive ACTH from plasma in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2994590" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Pituitary-adrenal axis rhythm disturbances in psychiatric depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2543547" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Two-site immunoradiometric assay for adrenocorticotrophin: a cautionary study about the reactivity to its precursor molecules.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16410667" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Malignant gastric carcinoid causing ectopic ACTH syndrome: discrepancy of plasma ACTH levels measured by different immunoradiometric assays.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8383142" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Proopiomelanocortin is the predominant adrenocorticotropin-related peptide in human cerebrospinal fluid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2547830" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Short loop adrenocorticotropin (ACTH) feedback after ACTH-(1-24) injection in man is an artifact of the immunoradiometric assay.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6313734" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Plasma distribution, disappearance half-time, metabolic clearance rate, and degradation of synthetic ovine corticotropin-releasing factor in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3494446" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Specific high-affinity binding protein for human corticotropin-releasing hormone in normal human plasma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2549150" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Isolation of the human plasma corticotrophin-releasing factor-binding protein.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3491832" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Immunoreactive corticotropin-releasing hormone in human plasma during pregnancy, labor, and delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3259975" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Circulating plasma corticotrophin-releasing factor-like immunoreactivity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3494036" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Plasma corticotropin-releasing hormone concentrations during pregnancy and parturition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7829610" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The corticotropin-releasing hormone (CRH) in normal and tumoral epithelial cells of human endometrium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2093479" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Binding of corticotropin-releasing hormone (CRH) in maternal and fetal plasma and in amniotic fluid.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1336818" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Placental corticotropin-releasing hormone and pituitary-adrenal function during pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8421097" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Corticotropin releasing hormone-binding protein (CRH-BP): plasma levels decrease during the third trimester of normal human pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2997301" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Immunoreactive corticotropin-releasing factor in human plasma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2556451" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Placental corticotropin-releasing hormone may be a stimulator of maternal pituitary adrenocorticotropic hormone secretion in humans.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2543179" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Plasma GHRH, CRH, ACTH, beta-endorphin, human placental lactogen, GH and cortisol concentrations at the third trimester of pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2225483" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Diurnal salivary cortisol patterns during pregnancy and after delivery: relationship to plasma corticotrophin-releasing-hormone.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3264436" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Carcinoma of the prostate with Cushing's syndrome. A case report with histochemical and chemical demonstration of immunoreactive corticotropin-releasing hormone in plasma and tumoral tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3035046" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : A phaeochromocytoma presenting with Cushing's syndrome associated with increased concentrations of circulating corticotrophin-releasing factor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3525603" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Cushing's syndrome secondary to ectopic corticotropin-releasing hormone-adrenocorticotropin secretion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7240368" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Human gamma-lipotropin radioimmunoassay: identification of immunoreactive gamma-lipotropin in human plasma and tissue.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/208078" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : beta-Lipotropin is the major opioid-like peptide of human pituitary and rat pars distalis: lack of significant beta-endorphin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6321535" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Synthetic ovine corticotropin-releasing hormone: simultaneous release of proopiolipomelanocortin peptides in man.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/174889" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Immunoreactive alpha-MSH and ACTH levels in rat plasma and pituitary.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6256410" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Simultaneous assay of immunoreactive beta-lipotropin, gamma-lipotropin, and beta-endorphin in plasma of normal human subjects, patients with ACTH/lipotropin hypersecretory syndromes, and patients undergoing chronic hemodialysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6088129" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Measurement of immunoreactive gamma-MSH in human plasma.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6269693" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Clonidine releases immunoreactive beta-endorphin from rat para distalis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6300165" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Measurement of N-terminal (1-76) of human proopiomelanocortin in human plasma: correlation with adrenocorticotropin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2543219" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Comparative assessment of ACTH and lipotropin plasma levels in the diagnosis and follow-up of patients with Cushing's syndrome: a study of 210 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8954027" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : High plasma proopiomelanocortin in aggressive adrenocorticotropin-secreting tumors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8636257" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Impaired processing of proopiomelanocortin in corticotroph macroadenomas.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
